AI Article Synopsis

  • * The exact cause of peripartum cardiomyopathy is unclear, although factors like age, lifestyle, and genetics may play a role; recent theories suggest that an abnormal form of prolactin may contribute to the heart damage.
  • * Ongoing research explores treatments like bromocriptine, a drug that inhibits prolactin, and highlights the importance of safe medication use during pregnancy and breastfeeding, particularly to protect both mothers and their babies.

Article Abstract

Peripartum cardiomyopathy is a disease that occurs during or after pregnancy and leads to a significant decline in cardiac function in previously healthy women. Peripartum cardiomyopathy has a varying prevalence among women depending on the part of the world where they live, but it is associated with a significant mortality and morbidity in this population. Therefore, timely diagnosis, treatment, and monitoring of this disease from its onset are of utmost importance. Although many risk factors are associated with the occurrence of peripartum cardiomyopathy, such as conditions of life, age of the woman, nutrient deficiencies, or multiple pregnancies, the exact cause of its onset remains unknown. Advances in research on the genetic associations with cardiomyopathies have provided a wealth of data indicating a possible association with peripartum cardiomyopathy, but due to numerous mutations and data inconsistencies, the exact connection remains unclear. Significant insights into the pathophysiological mechanisms underlying peripartum cardiomyopathy have been provided by the theory of an abnormal 16-kDa prolactin, which may be generated in an oxidative stress environment and lead to vascular and consequently myocardial damage. Recent studies supporting this disease mechanism also include research on the efficacy of bromocriptine (a prolactin synthesis inhibitor) in restoring cardiac function in affected patients. Despite significant progress in the research of this disease, there are still insufficient data on the safety of use of certain drugs treating heart failure during pregnancy and breastfeeding. Considering the metabolic changes that occur in different stages of pregnancy and the postpartum period, determining the correct dosing regimen of medications is of utmost importance not only for better treatment and survival of mothers but also for reducing the risk of toxic effects on the fetus.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11477285PMC
http://dx.doi.org/10.3390/ijms251910559DOI Listing

Publication Analysis

Top Keywords

peripartum cardiomyopathy
20
cardiac function
8
peripartum
6
cardiomyopathy
5
peripartum cardiomyopathy?
4
cardiomyopathy? yesterday
4
yesterday today
4
today tomorrow
4
tomorrow peripartum
4
disease
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!